Affinity Asset Advisors, LLC Verona Pharma PLC Transaction History

Affinity Asset Advisors, LLC

$560 Million
Q4 2024

A detailed history of Affinity Asset Advisors, LLC transactions in Verona Pharma PLC stock. As of the latest transaction made, Affinity Asset Advisors, LLC holds 660,000 shares of VRNA stock, worth $42.4 Million. This represents 5.48% of its overall portfolio holdings.

Number of Shares

660,000

Previous 650,000 1.54%

Holding current value

$42.4 Million

Previous $18.7 Million 63.9%

% of portfolio

5.48%

Previous 3.23%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$28.71 - $47.02 $287,100 - $470,200	10,000 Added 1.54%	660,000 $30.7 Million
Q3 2024 Nov 13, 2024	SELL	$15.46 - $30.16 $773,000 - $1.51 Million	-50,000 Reduced 7.14%	650,000 $18.7 Million
Q2 2024 Aug 14, 2024	SELL	$11.48 - $17.02 $1.35 Million - $2.01 Million	-117,833 Reduced 14.41%	700,000 $10.1 Million
Q1 2024 May 14, 2024	BUY	$15.3 - $20.24 $3.89 Million - $5.14 Million	254,009 Added 45.05%	817,833 $13.2 Million
Q4 2023 Feb 13, 2024	BUY	$11.94 - $20.47 $2.33 Million - $4 Million	195,495 Added 53.08%	563,824 $11.2 Million
Q3 2023 Nov 14, 2023	SELL	$16.3 - $22.09 $1.29 Million - $1.75 Million	-79,338 Reduced 17.72%	368,329 $6 Million
Q2 2023 Aug 14, 2023	SELL	$19.41 - $23.43 $100,039 - $120,758	-5,154 Reduced 1.14%	447,667 $9.46 Million
Q1 2023 May 15, 2023	BUY	$18.06 - $25.27 $2.53 Million - $3.55 Million	140,323 Added 44.9%	452,821 $9.09 Million
Q4 2022 Feb 13, 2023	SELL	$9.84 - $26.13 $369,019 - $979,927	-37,502 Reduced 10.71%	312,498 $8.17 Million
Q3 2022 Nov 14, 2022	BUY	$4.14 - $13.59 $1.45 Million - $4.76 Million	350,000 New	350,000 $3.58 Million

Others Institutions Holding VRNA

# of Institutions

217

Shares Held

70.5M

Call Options Held

1.4M

Put Options Held

299K

View Full List

About Verona Pharma plc

Ticker VRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,954,200
Market Cap $3.91B
Description
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...

More about VRNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Affinity Asset Advisors, LLC with notifications on news.

Account

Affinity Asset Advisors, LLC Verona Pharma PLC Transaction History